Bedoukian Research Inc. Overview
A three-year employee trend is not publicly disclosed. The aggregator figures suggest growth from about 80 in 2017 to somewhere above 100 by 2025, but the sources use different methods and should not be read as a series.
Bedoukian Research is a small, family-owned US maker of high-impact aroma chemicals, founded in 1972 and based in Danbury, Connecticut. It does not compete with the large flavor and fragrance houses in compounding. It sells single molecules to them and to other formulators: unsaturated aldehydes, leaf-alcohol derivatives, lactones, jasmonoids and similar materials that work at low dose. A second brand, BedoukianBio, applies the same multi-step organic synthesis to insect pheromones and repellent actives. A third activity is custom and toll manufacturing for pharmaceutical, biotech and agrochemical clients. The company's edge is chemistry depth and speed: R&I reports directly to the CEO and sits next to the plant. Its constraints are scale, a single manufacturing site and limited disclosure. Since the death of long-time president Dr. Robert Bedoukian in August 2024, the company has moved to professional management, appointing a non-family CEO in October 2025.
The company's own description. There is no annual report. The closest equivalent is the boilerplate in the 18 May 2026 press release, which describes a family-owned specialty chemical company founded in 1972 and headquartered in Danbury. It supplies aroma chemicals and blends for flavor, fragrance and personal care under the Bedoukian Flavor & Fragrance brand, and provides custom manufacturing for pharmaceutical, biotech and agrochemical clients. The October 2025 CEO announcement adds semiochemicals as a second served industry alongside flavor and fragrance.
Independent characterization. Bedoukian is an upstream ingredient manufacturer. It sits between commodity and fine-chemical feedstock suppliers and the compounders (flavor and fragrance houses) that blend ingredients into finished flavors and perfumes for consumer goods companies. Its catalog is weighted to "high-impact" molecules, meaning materials used at fractions of a percent in a formula. The 2026 featured fragrance list shows recommended odor evaluation levels of 0.1% to 10%. This positions the company in low-volume, high-value specialties, where purity, isomer control and reliable supply matter more than tonnage.
Revenue model. All evidence points to product sales (merchant sale of molecules by the kilogram) plus fee-based custom synthesis and toll processing. There is no indication of subscription or licensing revenue. Repellent actives are patented and offered as ingredients for others' formulations, which could involve licensing, but no licence terms are disclosed. The revenue mix across flavor, fragrance, pheromones and custom work is not publicly disclosed.
Value chain position.
End-markets. Per the company: food and beverage flavors, fine fragrance, personal care, home care and air care; agricultural, forestry, residential and stored-product pest management through BedoukianBio; and pharmaceutical, biotech, agrochemical and specialty chemical custom manufacturing.
Catalog size: conflicting figures. Sources differ and the discrepancy should be noted, not resolved by guesswork:
The differences probably reflect definitions (all catalog items versus actively promoted molecules), but this is not confirmed.
Strategy
There is no annual report or investor day. Strategy has to be read from press releases and management statements. Themes are paraphrased.
Financial targets and guidance. None are published. Cost programs, capex plans and growth targets are not publicly disclosed.
Products & Services
Pricing is by quotation and is not published. Launch years for individual molecules are generally not disclosed. Two historic exceptions are known: leaf alcohol chemistry dating to 1963, and Lactone of Cis Jasmone and cis-3-hexenyl salicylate supplied by 1973.
Fragrance ingredients: 2026 Featured Fragrance list
| Product (BRI no.) | Chemical identity | CAS | Odor character | Suggested evaluation level |
|---|---|---|---|---|
| HYDROFLEUR (279-SUS) | 6-Hydroxy-2,6-dimethylheptanal | 62439-42-3 | Fresh, watery-ozonic with raspberry and melon | 10% |
| Tridecanal (287) | Tridecanal | 10486-19-8 | Waxy citrus, grapefruit hint | 1% |
| PARMAVERT (310) | 2-Nonynal dimethyl acetal | 13257-44-8 | Green floral, violet leaf | 1% |
| e,z-2,6-Nonadien-1-al diethyl acetal (317) | As named | 67674-36-6 | Violet and melon | 0.1% |
| ORRISOL (330-SUS) | 3,6-Nonadienol | 76649-25-7 | Green cucumber, orris, honeydew | 5% |
| 3,6-Nonadien-1-yl acetate (338) | As named | 76649-26-8 | Soft fresh green | 1% |
| VALENCIAL FCC (356-SUS) | trans-2-Dodecenal | 20407-84-5 | Aldehydic orange peel | 1% |
| CANTALAL (359) | cis-5-Octenal | 41547-22-2 | Watermelon with citrus | 0.1% |
| CARDAMOM ALDEHYDE FCC (381) | cis-4-Decenal | 21662-09-9 | Spicy aldehydic citrus, crushed cardamom | 1% |
| TANGELAL (387) | cis-4-Dodecenal | 21944-98-9 | Tangerine and orange peel | 1% |
| APRITONE (410) | 2-(3,7-Dimethyl-2,6-octadienyl)cyclopentanone | 68133-79-9 | Apricot and peach with jasmine | 10% |
| LACTONE OF CIS JASMONE (411-SUS) | 5-(3Z)-3-Hexenyldihydro-5-methyl-2(3H)-furanone | 70851-61-5 | Creamy jasmine, white floral | 10% |
| GUAVANATE (493) | Methyl (Z)-5-octenoate | 41654-15-3 | Ripe tropical, sweet green fruit | 1% |
| CEREZOATE (512) | Ethyl 2-methyl-3-pentenoate | 1617-23-8 | Juicy fruit, black cherry | 1% |
| Methyl Anjoulate (535) | Methyl (4E)-4,7-octadienoate | 189440-77-5 | Green sweet pear | 5% |
| 2-Octen-4-one (614) | As named | 4643-27-0 | Green fruity, pineapple and berry | 1% |
| VIONIL 10% in DPG (640DPG) | 2,6-Nonadienenitrile | Mixture | Cucumber, violet leaf, orris | 1% |
| NUEZATE (728) | Ethyl 3-methyl-2-oxopentanoate | 26516-27-8 | Gourmand walnut and hazelnut, maple | 1% |
| TERRASOL FCC (818-SUS) | See note | 18368-91-7 | Earthy, woody, camphoraceous, patchouli-like | 1% |
| Ethyl vanillin propylene glycol acetal (831) | As named | 68527-76-4 | Vanilla with clove-like spice | 5% |
| 3-Methyl-2,4-nonanedione (841) | As named | 113486-29-6 | Anisic, herbal green, lactonic | 0.1% |
| LAVENDER ALDEHYDE FCC (857-SUS) | 2-Isopropyl-5-methyl-2-hexenal | 35158-25-9 | Herbaceous lavender, cocoa, bergamot | 1% |
| LIMEDIENE (962) | Methyl cyclohexadiene | 30640-46-1 | Diffusive lemon-lime top note | 0.1% |
| FRUITALEUR (9840) | Ethyl 2-methyl-3-pentenoate | 1617-23-8 | Tropical fruit, pear and pineapple | 1% |
Source: company "2026 Fragrance Molecule Reference" page (last modified 21 August 2026). The company says the list is curated yearly by leadership, sales and R&D. Odor descriptions are paraphrased.
Flavor ingredients
The company publishes a parallel Featured Flavor list and a Flavor i-Catalog. Site metadata names the following materials in connection with the featured lists: Lavender Aldehyde, Terrasol, Nuezate, Cerezoate, Guavanate, Decadionate, Jasmone, Apritone, decanal, Tangelal, Cardamom Aldehyde, Valencial, Orrisol, 3-methyl-2,4-nonanedione, methyltridecanal, heptanal and spilanthol. Several carry "FCC" grade labels, indicating food-grade specification. The company demonstrates flavor materials in water and on blotter (September 2026 news post).
Sustainable ingredients ("-SUS" grades)
Grades with the "-SUS" suffix (279-SUS, 330-SUS, 356-SUS, 411-SUS, 818-SUS, 857-SUS, and 885-SUS and 894-SUS referenced in a 2023 newsletter) form the Sustainable Ingredients range.
BedoukianBio: pheromones and semiochemicals
| Offering | Description | Target customer | Source |
|---|---|---|---|
| Technical-grade insect pheromones | Active ingredients for monitoring, mass trapping and mating disruption in agriculture, forestry, residential and storage settings; about 50 pheromones cited c. 2023 | Pheromone product formulators, crop protection companies | Trade press; BedoukianBio |
| Bed bug surface repellent active | Patented, DEET-free, food-grade active; company cites a 99% reduction in bed bug feeding in simulated bedroom tests and activity against cockroaches, scorpions, spiders and ants; sold as an ingredient, not a finished product | Pest-control product formulators | Pest Management Professional magazine |
| Biting arthropod repellents | Patent families on control and repellency of biting arthropods and synergistic formulations | Repellent formulators | Patent records |
| Stink bug repellent candidates | Eight candidate repellents supplied for Virginia Tech testing on brown marmorated stink bug (2017) | Research stage | Research presentation |
| Trademarks | CLOAK & SCATTER (2007, insect lure/repellent); PHEROTRAK (2024, pheromone-related) | — | IPqwery |
The company says it holds a leading number of US registrations in EPA's pesticide product system for this category.
Services
| Service | Description | Source |
|---|---|---|
| Custom products | Custom synthesis of molecules to customer specification | Company website |
| Toll processing / custom manufacturing | Contract manufacture for pharmaceutical, biotech, agrochemical and specialty chemical clients | Company press release, May 2026 |
| Applications Lab demonstrations | Materials shown neat, in accord and in finished application; with/without comparisons and cost-in-use | Company news post, Sept 2026 |
| i-Catalogs | Online fragrance and flavor catalogs searchable by character, application and stability | Company website |
Financial Narrative
Bedoukian publishes no financial statements. No audited revenue, profit, balance sheet or cash flow figure exists in the public domain. The tables below keep the requested structure with blank cells. Nothing is estimated.
Income statement (blank = not publicly disclosed)
Balance sheet (blank = not publicly disclosed)
Cash flow and ratios (blank = not publicly disclosed)
What can be said about scale.
Commentary. The aggregator estimate and the headcount conflict. Revenue per employee in specialty aroma chemicals rarely supports hundreds of millions of dollars from about 126 people. Both data points are reported here and the discrepancy is unresolved. Any revenue figure used in downstream analysis should come from a paid private-company database or direct inquiry, and be labelled as an estimate. The one qualitative margin signal on record is the R&I director's May 2026 statement that a new synthesis route for a strategically important product, now in scale-up, should bring a meaningful margin increase.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line | Brand | Contents |
|---|---|---|
Flavor and fragrance ingredients | Bedoukian Flavor & Fragrance | Aroma chemicals and blends for flavor, fragrance and personal care; featured ingredient lists; "-SUS" sustainable grades |
Pheromones and semiochemicals | BedoukianBio | Technical-grade pheromones and semiochemicals for monitoring, mass trapping, mating disruption and repellency; patented repellent actives |
Custom manufacturing and toll processing | Bedoukian (Custom Products; Toll Processing) | Contract synthesis for pharma, biotech, agrochemical and specialty chemical clients |
Group Entities
| Entity | Location | Role | Source |
|---|---|---|---|
Bedoukian Research, Inc. | Danbury, Connecticut | Parent; manufacturing, R&I, Americas sales | Company website |
Bedoukian Research Switzerland GmbH | Switzerland | Sales for Europe, Africa and the Middle East | Company contact pages |
Bedoukian Research Singapore Pte Ltd | Singapore | Sales for India, China, Japan, the rest of Asia, Australia and New Zealand | Company contact pages |
Financial Analysis
| Indicator | Value | Source | Reliability |
|---|---|---|---|
Sales in 1994 | First month above USD 1 million, implying annualized sales of roughly USD 10–12 million at that time | Company timeline | Company-stated milestone; the annualization is an inference |
Headcount | About 80 (2017); 126 (2025 profile) | Senator Murphy release; PitchBook | Moderate |
Third-party revenue estimate | "Mid hundreds of millions" | LeadIQ | Low. This is a modelled aggregator figure and is hard to reconcile with a workforce of roughly 100–130 at a single plant |
EPA penalty | USD 671,899 paid under a 2025 settlement | EPA EAB Final Order | High; the only hard dollar figure on record for the period |
Territory Details
| Territory | Coverage model | Entity or partner |
|---|---|---|
North and South America | Direct sales | Bedoukian Research, Inc. |
Europe, Africa, Turkey, UAE and Middle East | Direct sales | Bedoukian Research Switzerland GmbH |
India, China, Taiwan, Japan, Korea, Southeast Asia, Australia, New Zealand | Direct sales plus distributors | Bedoukian Research Singapore Pte Ltd |
Regional distribution | Distributors attending the 2026 summit: BLH, Ashapura, Zoteq, Taytonn, Yinca and Stort | Company news post, Sept 2026 |
Capital Markets
| Item | Status |
|---|---|
Credit ratings (Moody's, S&P, Fitch) | None found |
Outside investors | None known |
Analyst Conclusions
Guidance and consensus. There is no management guidance and no analyst consensus. The only forward-looking statements on record are qualitative: a growth and innovation phase under the new CEO, a 2027 commercial plan built with distributors, and a new process route expected to lift margins.
Bull case
-
Margin expansion from process innovation. Management has pointed to a meaningful margin gain on a strategically important product, and the new R&I head has four years of plant experience to deliver it.
-
Professional leadership with relevant experience. A CEO from McCormick's R&I leadership and a separate non-family chair give the company management depth it did not have under a single owner-president.
-
Two differentiated platforms. High-impact aroma molecules are less exposed to commodity price competition than bulk aroma chemicals, and BedoukianBio gives exposure to biological pest control.
Bear case
-
Compliance and regulatory drag. The EPA case showed weak controls over new-chemical notifications across six years. Under the settlement, further lapses would be costly, and tighter TSCA practice slows the molecule launches the company depends on.
-
Scale and concentration. One plant, roughly 126 people and customers that are also competitors leave little room for error, while Chinese producers are taking share from even the largest houses.
-
Unproven partnerships and thin IP. Fermentation and renewable-route partnerships announced since 2021 have produced no disclosed commercial launch, and the patent estate centers on a deceased inventor.
Catalysts and monitorables (next 12 months)
Analyst verdict
What the record does support is a clear picture of a business in transition.
For five decades the company was run by two generations of chemist-owners who built a respected niche in difficult, high-impact aroma molecules and later added insect pheromones and repellents. That model ended in August 2024 with Robert Bedoukian's death. The family has since chosen professional management: a non-family chair, a CEO recruited from McCormick, and an R&I head promoted from the plant floor with a mandate to tie research to scale-up and margin.
The early signs are sensible. The September 2026 distributor summit shows a more structured commercial approach, and management is talking about margin, pipeline gaps and customer feedback instead of heritage. The 2025 EPA settlement is the main blemish. It revealed weak regulatory controls over several years and cost about USD 0.67 million, but it also forced an environmental management system and independent audits that a company of this size might not otherwise have adopted.
The structural risks remain: one plant, small scale, customers that also compete, and Asian producers pressing on price. The growth options in fermentation, renewable pheromone routes and repellent actives are real but unproven commercially.
For a counterparty, supplier or adviser, Bedoukian is a credible specialist with strong technical standing and a management team that appears open to outside input. For any valuation or credit view, the public record is insufficient. Revenue, margins and leverage must come from the company or a verified private-company data source. The aggregator revenue estimate in circulation conflicts with the headcount and should not be relied on. Ownership intentions are the key unknown to watch.
Source notes and verification flags
| Flag | Detail |
|---|---|
| Company type | Brief says public; evidence shows private and family-owned |
| Financials | No audited figures exist publicly; all financial cells left blank |
| Revenue estimate conflict | LeadIQ suggests mid hundreds of millions; headcount of about 126 (PitchBook) makes this doubtful; unresolved |
| Catalog size conflict | 300+, 450+50 and 500+ figures cited at different dates |
| Featured list errors | TERRASOL chemical name and the CEREZOATE/FRUITALEUR CAS duplication on the company page |
| — | First P2 Science agreement (c. 2014); Ardra collaboration (c. 2021); P2 pheromone JDA (c. April 2023) |
| Roles not re-verified | CFO and several director-level roles drawn from 2023–2024 sources |
| Peer data | Givaudan FY2025 verified against its results release; Symrise and IFF FY2024 figures not re-verified |
| EMS deadline | 3 November 2025 is derived from the 270-day term, not stated in the order |
| Market sizes | Not sourced; order-of-magnitude only |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure and background | Source |
|---|---|---|---|
Robert Sobel, Ph.D. | Chief Executive Officer | Appointed 20 Oct 2025; over 25 years in scientific and technology leadership; most recently VP Research & Innovation at McCormick | Company press release |
Robert Weinstein, Ph.D. | Chair of the Board | Named as Chair in Oct 2025; start date and background not disclosed in sources retrieved | Company press release |
Paul Decker | Board member | Listed as board member from Jan 2022 | Crunchbase |
Jim Zitelli | Chief Financial Officer | — | Company press archive |
Krzysztof Swierczek, Ph.D. | Director of Research and Innovation | Joined R&I as a chemist in 2012; Technical Production Manager 2022–2026; named Director 18 May 2026 | Company press release |
Maha Ali | Applications Lab Director | Quoted Sept 2026 | Company news post |
David Bedoukian | VP of Sales (as listed May 2024) | Third generation; joined 2006 | Wiza; company timeline |
Matt Bedoukian | Role not confirmed | Third generation; joined 2006 | Company timeline |
Clarisa Braier | Sales, North and South America | Joined Jan 2024 | Company press release |
Eleanor Badhe | Sales, Europe, Africa, Middle East | Bedoukian Research Switzerland GmbH | Company contact pages |
Elvin Lim | Sales, Asia-Pacific | Bedoukian Research Singapore Pte Ltd | Company contact pages |
Executive Leadership Team
| Name | Role | Period |
|---|---|---|
Dr. Paul Bedoukian | Founder | 1972 until his death (FMA award given posthumously in 2002) |
Dr. Robert H. Bedoukian | President | 1986 to 30 August 2024; BS chemical engineering, Tufts (1970); PhD organic chemistry, Purdue (1975); founder of BedoukianBio |
Competitive Landscape
Key Competitors
| Competitor | Type | Relevance to Bedoukian |
|---|---|---|
Givaudan (Fragrance Ingredients) | Listed, Switzerland | Customer and competitor; captive and merchant aroma molecules |
dsm-firmenich | Listed, Switzerland/Netherlands | Customer and competitor; large ingredients division |
IFF | Listed, USA | Customer and competitor |
Symrise | Listed, Germany | Customer and competitor; strong aroma molecules business |
BASF Aroma Ingredients | Division of listed group | Large-volume aroma chemicals |
Takasago | Listed, Japan | Specialty aroma chemicals, chiral chemistry |
Zeon Corporation | Listed, Japan | Leaf alcohol and green-note chemistry, overlapping Bedoukian's heritage class |
Privi Speciality Chemicals | Listed, India | Cost-competitive aroma chemicals |
Eternis Fine Chemicals | Private, India | Aroma chemicals at scale |
Vigon International (Azelis) | Distributor/manufacturer, USA | US specialty flavor and fragrance ingredients |
Axxence Aromatic | Private, Germany | Natural aroma chemicals; named as a competitor by CB Insights |
Penta Manufacturing; Advanced Biotech | Private, USA | US specialty and natural aroma chemicals |
Shin-Etsu Chemical | Listed, Japan | Major pheromone active producer |
Suterra (Wonderful Company) | Private, USA | Mating disruption products |
Provivi | Private, USA | Lower-cost pheromone synthesis |
ISCA | Private, USA | Semiochemical formulations |
Russell IPM | Private, UK | Pheromone and trapping products |
Peer Comparison FY2025
| Metric | Bedoukian Research | Givaudan (FY2025) | — | — |
|---|---|---|---|---|
Revenue | — | CHF 7,472 M | approx. EUR 5.0 bn | approx. USD 11.5 bn |
Growth | — | 5.1% like-for-like | approx. 8.7% organic | approx. 6% currency-neutral comparable |
EBITDA margin | — | 23.4% (24.2% comparable) | approx. 20.7% | approx. 19% (adjusted operating EBITDA) |
Employees | approx. 126 (PitchBook) | — | — | — |
“—” = not publicly disclosed.
Recent Developments
The register is not padded.



